RA
VNDA icon

Royce & Associates’s Vanda Pharmaceuticals VNDA Stock Holding History

Royce & Associates’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,821
Closed -$94.7K – 957
2022
Q4 		$94.7K Sell
12,821
-10,334
-45% -$101K ﹤0.01% 890
2022
Q3 		$229K Sell
23,155
-52,908
-70% -$559K ﹤0.01% 879
2022
Q2 		$829K Sell
76,063
-163,564
-68% -$1.69M 0.01% 778
2022
Q1 		$2.71M Buy
239,627
+119,329
+99% +$1.57M 0.02% 670
2021
Q4 		$1.89M Sell
120,298
-5,119
-4% -$89.2K 0.01% 734
2021
Q3 		$2.15M Sell
125,417
-7,994
-6% -$140K 0.02% 734
2021
Q2 		$2.87M Sell
133,411
-3,347
-2% -$59.9K 0.02% 704
2021
Q1 		$2.05M Buy
136,758
+3,369
+3% +$54.5K 0.01% 751
2020
Q4 		$1.75M Buy
133,389
+63,841
+92% +$768K 0.01% 750
2020
Q3 		$672K Buy
69,548
+35,342
+103% +$378K 0.01% 822
2020
Q2 		$391K Buy
34,206
+5,919
+21% +$67K ﹤0.01% 881
2020
Q1 		$293K Buy
28,287
+808
+3% +$10K ﹤0.01% 886
2019
Q4 		$451K Buy
27,479
+13,193
+92% +$199K ﹤0.01% 901
2019
Q3 		$190K Buy
+14,286
New +$199K ﹤0.01% 980

Other funds holding VNDA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Royce & Associates's VNDA Position: Q1 2023 in Review

Royce & Associates sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 12,821 shares — an estimated $94.7K sold.

Royce & Associates first reported a position in VNDA in Q3 2019 and held it in 14 quarters. The position peaked at $2.87M in Q2 2021. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

  • Royce & Associates reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Royce & Associates sold 12,821 Vanda Pharmaceuticals shares in Q1 2023, an estimated $94.7K.
  • Royce & Associates first reported a position in Vanda Pharmaceuticals in Q3 2019 and held it in 14 quarters.
  • Royce & Associates's Vanda Pharmaceuticals position peaked at $2.87M in Q2 2021.
  • 177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Royce & Associates's 13F filing for Q1 2023, filed 4 May 2023.